Facebook advertises its returns to corporations,

FXall, the electronic trading platform formerly known as FX Alliance, which is backed by a range of financial services firms, will offer its shares at between $13.50 and $15.50 when it floats.

The oncological drug developer backed by the firm of SR One's founder outstrips expectations as it raises $55m from its initial public offering, seeing its price rise after the first day of trading.

The agricultural and biomass technology firm is looking to raise $100m when it floats, with shareholders including Monsanto set for a return on their investment.

GlaxoSmithKline-backed ChemoCentryx is looking to raise up to $64m when it floats, hot on the heels of fellow biopharmaceutical company Verastem.

The biotechnology researcher, backed by a GlaxoSmithKline-linked venture capital firm, has set the range for its shares for its initial public offering at between $9 and $11.

With 48 million shares issued, worth an assumed $14.85 each, the market capitalization of AVG would be $712.8m.

The Duchossis-backed computer networking firm is looking to raise up to $125m when it floats.

Corporate-backed biodiesel producer and supplier the Renewable Energy Group sets the range of its IPO, and looks to raise as much as $100m.